In June 2010, a supplemental indication was granted for maintenance treatment of locally advanced or metastatic NSCLC, with a post-marketing commitment to conduct an RCT including all patients and measure endothelial growth factor receptor (EGFR) mutation status and another trial restricted to patients with EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.